A diagnosis of gastroparesis after using semaglutide is critical to your claim
GLP-1 agonists are a class of medications that help treat type II diabetes. Recently, they have also been marketed for weight loss. GLP-1 agonists are sold under the brand names Ozempic, Wegovy, and Rybelsus, all manufactured by Novo Nordisk.
In the past few years, many patients taking these drugs have experienced serious side effects, like gastroparesis and bowel obstruction. Gastroparesis, or stomach paralysis, is a condition in which the muscles and nerves of the stomach weaken, causing food to stay longer in the stomach instead of moving to the small intestine. This is a chronic condition that currently has no cure.
If you or your loved one have experienced any of these symptoms after starting semaglutide:
- Severe nausea
- Intense vomiting
- Abdominal pain
- Abdominal bloating
- Extreme dehydration
Then we urge you to seek medical attention immediately. An accurate diagnosis of gastroparesis will be the basis of your claim against the manufacturer. Other eligibility criteria can be found here.
Our team can help you get the maximum compensation you deserve
Novo Nordisk failed to disclose the extent of the side effects of these drugs, and they can be held liable. After your diagnosis, reach out to us with your medical records, and we will determine whether or not you have the possibility of claiming compensation from the manufacturer.
Take note that only those diagnosed with gastroparesis or bowel obstructions may benefit from financial compensation from Novo Nordisk. Aside from a proper diagnosis from a medical professional, other documents that may support your claim are:
- A prescription for Ozempic, Wegovy, or Rybelsus
- Proof of you having taken these drugs (e.g., medication packaging with your name)
If your claim has a strong basis, we will do all the hard work for you so that you can focus on your recovery while you get the compensation you rightly deserve.
